Tiny silica particles engineered to target prostate cancer caused tumor cells to self-destruct and boosted the immune system in mouse studies, according to research published in ScienceDaily. Combined with immunotherapy, the treatment produced complete remissions in multiple mice.
The approach involves nanoparticles that selectively deliver a therapeutic payload to cancer cells, sparing healthy tissue. This precision could reduce side effects common with conventional treatments like chemotherapy.
In the preclinical trials, the nanoparticles not only eliminated tumors but also triggered a lasting immune memory. Researchers observed that the immune system could later recognize and attack cancer cells if they reappeared.
The findings raise hopes for a new treatment paradigm for aggressive prostate cancer, which is notoriously difficult to treat in advanced stages. However, human trials are still years away.
Experts caution that results in mice often fail to translate to humans. The study's lead author emphasized that the next step is safety testing in larger animals before any human trials can begin.